D/E 0.42 — near the Healthcare debt median (≈60th pctile)
P/E18.8xA-
P/E 18.8 — cheaper than most Healthcare peers (≈25th pctile)
PEG0.54A-
PEG 0.54 — strong; Lynch's preferred zone
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 72
Quality0.65
Growth0.97
Value0.80
Why this score
Short track record
Entry · Margin of safety
52-week rangeNear 52-week low
59% off the 12-month high
vs DCF fair value27% belowest. fair value ~$61
Quality signals · context only
Gross profitability32% · B+gross profit ÷ total assets (Novy-Marx)
ROIC9.8% · Breturn on invested capital — not score-weighted
Why now
Medical Devices · market cap $66.6b. Down 59% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.54 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $74.55 (implying +66% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 59% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $74.55 (29-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $94.12 at ~16% CAGR — dividend + buyback compounding. 10 yr $120.71 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · BSX
Trend
0.0 over 14 daily scores
From 72.0 (Jun 22) → 72.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · BSX
$
%
%
Shares to buy
44
Position size
$1,972
3.9% of portfolio
Stop price
$33.61
25% below $44.81
$ at risk if stopped
$492.96
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Boston Scientific Corporation (BSX): score, valuation & FAQ
Boston Scientific Corporation (BSX) is a Medical Devices company that scores 72 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-), PEG (A-) and Rev (B+). On valuation, BSX sits about 27% below our discounted-cash-flow fair value (a margin of safety).
Is BSX a good stock to buy?
Bull Rankings scores BSX 72 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-), PEG (A-) and Rev (B+). A score is a quantitative screen of Boston Scientific Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does BSX score 72 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). BSX earns its highest marks on P/E (A-), PEG (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is BSX overvalued or undervalued?
Based on $44.81, BSX sits about 27% below our discounted-cash-flow fair value (a margin of safety). It trades at a 18.8x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in BSX?
Down 59% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.